Market conditions and purchasing guidelines for Pralatrexate Injection

Pralatrexate, whose brand name is Folotyn, is an antimetabolite drug used to treat malignant tumors, mainly used to treat peripheral T cell lymphoma. The market cost of pralatrexate for intravenous injection (20mg/ml) in the United States is approximately $$4,195 per milliliter. This makes its treatment relatively expensive, especially for patients who require long-term treatment. Since the drug is not currently available in China, domestic patients usually need to purchase it through formal overseas channels, which may make it difficult and expensive to obtain the drug. Therefore, patients need to pay special attention to the source and cost of the drug when using pralatrexate, and make relevant financial planning and preparations.

Platrexate injection is an antimetabolite drug mainly used to treat relapsed or refractory peripheral T cell lymphoma (PTCL). As an anti-cancer drug, pralatrexate inhibits the proliferation of tumor cells by inhibiting key enzymes such as dihydrofolate reductase (DHFR) and interfering with cells' DNA synthesis and repair.

The efficacy of pralatrexate has been demonstrated clinically, particularly in patients with peripheral TT cell lymphoma who are refractory to conventional treatments. FDAapproved pralatrexate for the treatment of these patients in 2011, and its clinical trials have shown that pralatrexate can significantly extend the progression-free survival (PFS) and overall survival (OS) of patients. Compared with other chemotherapy drugs, pralatrexate has relatively controllable side effects and can relatively preserve the function of normal tissues.

However, the side effects of pralatrexate include bone marrow suppression (such as anemia, leukopenia, thrombocytopenia), gastrointestinal discomfort (such as oral ulcers, nausea, vomiting), etc., so hematology and liver function indicators need to be closely monitored during use. In addition, the price of pralatrexate is relatively high, especially in areas without medical insurance coverage, and patients may face a greater financial burden.

Reference materials:https://www.drugs.com/pro/pralatrexate-injection.html